^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Title:
lenvatinib (Lenvima) is accepted for use within NHSScotland
Published date:
04/08/2019
Excerpt:
lenvatinib (Lenvima) is accepted for use within NHSScotland...as monotherapy for the treatment of adult patients with advanced
or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
Source:
Title:
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA® (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
Published date:
09/05/2018
Excerpt:
...Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the China National Medical Products Administration (NMPA) approved the kinase inhibitor LENVIMA® (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Source:
Title:
Anticancer Agent LENVIMA® Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Published date:
03/23/2018
Excerpt:
...Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA® (generic name: lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC).
Source:
Published date:
05/28/2015
Excerpt:
Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Source:
Excerpt:
LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Source:
Title:
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Published date:
11/16/2020
Excerpt:
Recommendations...First-Line Therapy...Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors (TKIs) sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC…Second-Line Therapy...second-line therapy with a TKI (ie, sorafenib, lenvatinib, cabozantinib, or regorafenib) may be recommended...second-line therapy with another TKI (cabozantinib or regorafenib), ramucirumab (AFP ≥ 400 ng/mL)...
DOI:
0.1200/JCO.20.02672 Journal of Clinical Oncology
Source:
Excerpt:
Hepatocellular carcinoma: Other Recommended Regimens....Lenvatinib (Child - Pugh Calss A only) (category 1)
Source:
Title:
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Management of advanced disease...Lenvatinib showed non-inferiority efficacy compared with sorafenib, and can be considered as first-line therapy in patients with advanced HCC without main portal vein invasion, clear bile duct invasion and 50% of tumour to total liver volume occupancy, pending EMA approval [I, A]
DOI:
10.1093/annonc/mdy308
Source:
Title:
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
Published date:
11/12/2019
Excerpt:
Median OS was 17.6 months for LEN vs. 17.8 months for SOR (HR 0.90; 95% CI 0.62–1.29). LEN showed statistically significant improvements over SOR in PFS (7.2 months vs. 4.6 months) and ORR (29.6% vs. 6.9%).
DOI:
https://doi.org/10.1007/s00535-019-01642-1
Trial ID:
